drugset / Trial / NCT03169985

Randomized Controlled Trial of Moderate-Intensity Rosuvastatin With Ezetimibe Combination Therapy Versus High-Intensity Rosuvastatin on Progression of Coronary Atherosclerotic Plaque

NCT03169985

Phase 4 Active not recruiting 280 enrolled Samsung Medical Center Hanmi Pharmaceutical Company Limited · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The aim of this prospective, open-label, randomized, single center study is to compare the effect of usual dose rosuvastatin plus ezetimibe and high-dose rosuvastatin on modifying atherosclerotic plaque.

Timeline

Start
2017-07-12
Primary completion
2027-01-28
Completion
2027-01-28

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ezetimibe Unknown 10 mg Oral
Comparator Rosuvastatin Small molecule 10 mg Oral
Comparator Rosuvastatin Small molecule 20 mg Oral